临试的主办方为当地国机构，疫苗厂家只是参与者(co-)和金主（sponser)。

https://clinicaltrials.gov/ct2/show/NCT04526990

 

这个里面介绍了三期临试所在国家和地区

https://en.wikipedia.org/wiki/Ad5-nCoV

 

中国没有足够感染者进行三期，寻求广泛的国际合作。

这个该疫苗的三期方案及实施情况 https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio/china-cansinobios-covid-19-vaccine-trials-recruit-over-20000-people-idUSKBN28V1N8

 

Phase 3 trials for CanSinoBIO's candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed.

 

 

这个与俄罗斯合作的数据报道

https://www.reuters.com/article/us-health-coronavirus-russia-china/chinese-covid-19-vaccine-ad5-ncov-shows-high-antibody-levels-at-russian-trial-ifax-idUSKBN29J123

MOSCOW (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit

 

所有跟帖： 

• 中国开发的疫苗 -TBz- ♂ (125 bytes) () 02/09/2021 postreply 08:38:36

• 唉，话语权取决于国之实力啊。相信用不上十年，在这个领域，中国将有主导权 -fuz- ♂ (0 bytes) () 02/09/2021 postreply 08:51:54

• 向中国和全世界公布三期结果，需要话语权吗？我不明白。 -TBz- ♂ (200 bytes) () 02/09/2021 postreply 08:59:58

• 当年SARS, 疫情爆发传遍大江南北，过了两个月居然没搞明白病原体是啥。那才是大囯的耻辱！ -fuz- ♂ (4861 bytes) () 02/09/2021 postreply 09:00:20